ALXN2220 for Cardiomyopathy

(LTSAFE-ALXN Trial)

Not yet recruiting at 173 trial locations
Age: Any Age
Sex: Any
Trial Phase: Phase 3
Sponsor: Alexion Pharmaceuticals, Inc.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study ALXN2220-ATTRCM-301.

Are You a Good Fit for This Trial?

Inclusion Criteria

Participant, or legally authorized representative where relevant and allowed by law, is willing and able to comply with all study requirements and to provide signed informed consent
My sex is male or female based on my chromosomes and reproductive organs.
Participants who have completed the Blinded Treatment Period (including the PC visit) of Study 301

Exclusion Criteria

Participants who permanently discontinued study intervention in Study 301
Participants who withdrew full consent during Study 301
I do not have allergies to proteins or ingredients in ALXN2220.
See 3 more

What Are the Treatments Tested in This Trial?

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: ALXN2220Experimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

Alexion Pharmaceuticals, Inc.

Lead Sponsor

Trials
267
Recruited
141,000+
Dr. Alberto R. Martinez profile image

Dr. Alberto R. Martinez

Alexion Pharmaceuticals, Inc.

Chief Medical Officer since 2010

MD from University of Sao Paulo

Marc Dunoyer profile image

Marc Dunoyer

Alexion Pharmaceuticals, Inc.

Chief Executive Officer since 2021

PhD in Molecular Biology